Collagen Solutions (COS)

Sector:

Health Care

Index:

FTSE AIM All-Share

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 3.20p
   
  • Change Today:
      0.000p
  • 52 Week High: 4.93
  • 52 Week Low: 2.48
  • Currency: UK Pounds
  • Shares Issued: 324.52m
  • Volume: 0
  • Market Cap: £10.38m

Collagen Solutions sees good uptick in revenue

By Josh White

Date: Tuesday 23 Oct 2018

LONDON (ShareCast) - (Sharecast News) - Medical grade collagen-based biomaterials manufacturer Collagen Solutions updated the market on its trading for the six months ended 30 September on Tuesday, reporting that revenue and other income was expected to be £2.10m.
The AIM-traded company said that would represent a 13% increase on the prior year.

Revenue performance had been buoyed by new development agreements closed in the first quarter of the financial year, which the board said had more than offset previously-announced delays in customer projects and inventory adjustments.

As it had anticipated, its development business would comprise nearly half of the firm's overall business in the full financial year.

New customer acquisition continued, with nine new customer deals representing an increase in the number of new customers over the same period last year, which was eight.

Collagen Solutions said the average expected value of those customer acquisitions also increased.

In addition, the tissue business unit had several pending agreements, which typically take three to six months to negotiate, with supply agreements expected to follow within a further 12 to 18 months.

"We remain on track to meet our key initiatives for the year including achieving our commercial execution plans and financial performance objectives in line with market expectations," said chief executive officer Jamal Rushdy.

"We are also continuing our planned rolling submission of data to support our goal of obtaining the CE Mark for 'ChondroMimetic' this financial year.

"We are in negotiations with multiple distributors which we expect to conclude ahead of the limited user release planned to follow the ChondroMimetic CE Mark."

Operationally, Rushdy said the firm's New Zealand restructuring initiative was delivering the expected synergies and benefits according to plan, with the New Zealand team now "fully focused" on the tissue business.

"We are pleased with our progress so far.

"Finally, we will continue to deliver more visibility and metrics to our investors relating to the value and progress within our core business."

Collagen Solutions said it would announce its interim results for the six months ended 30 September on 4 December.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

COS Market Data

Currency UK Pounds
Share Price 3.20p
Change Today 0.000p
% Change 0.00 %
52 Week High 4.93
52 Week Low 2.48
Volume 0
Shares Issued 324.52m
Market Cap £10.38m

COS Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.63% above the market average46.63% above the market average46.63% above the market average46.63% above the market average46.63% above the market average
52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average
Price Trend
22.93% above the market average22.93% above the market average22.93% above the market average22.93% above the market average22.93% above the market average
36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average
Income Not Available
Growth
2.42% below the market average2.42% below the market average2.42% below the market average2.42% below the market average2.42% below the market average
Sector averageSector averageSector averageSector averageSector average

COS Dividends

No dividends found

Trades for --2018

Time Volume / Share Price
0 @ 0.000p

COS Key Personnel

Chair David Evans
CEO Jamal Rushdy
CFO Hilary Spence
COO Tom Hyland

Top of Page